Sep 17, 2025
Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
Aug 18, 2025
Skyhawk Therapeutics Announces Strategic Collaboration with Merck KGaA, Darmstadt, Germany to Discover Novel RNA-Targeting Small Molecules for Neurological Disorders
Dec 09, 2024
Skyhawk Therapeutics Receives Australian Regulatory Approval to Extend SKY-0515 Treatment Duration in Phase 1 Huntington's Disease Patient Trial
Nov 21, 2024
Skyhawk Therapeutics to Present Preclinical Data of SKY-1214 Combination Treatment in Hematologic Cancers at the 66th American Society of Hematology Annual Meeting
Oct 24, 2024
Skyhawk Therapeutics Presents Compelling Preclinical Data on SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
Oct 16, 2024
Skyhawk Therapeutics to Present Preclinical Data on SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
Sep 11, 2024
Skyhawk Therapeutics to Present Additional Positive Topline Data from Parts A and B of Phase 1 Clinical Trial of SKY-0515 at European Huntington's Disease Network and Enroll-HD 2024
Feb 28, 2024
Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease
Dec 22, 2020
Filmmaker Bill Haney Wins Gold Medal From World's Leading Journal Of Scientific Research For Jim Allison: Breakthrough
May 12, 2020
Skyhawk Therapeutics Announces Expansion of its Collaboration Agreement with Merck to Discover and Develop Novel Small Molecules that Modulate RNA Splicing
Nov 12, 2019
Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing
Sep 04, 2019
RNA Expert Dr. Phillip Sharp Joins as Advisor to Skyhawk Therapeutics
Jul 08, 2019
Skyhawk Therapeutics Announces Collaboration Agreement with Merck to Discover and Develop Novel Small Molecules that Modulate RNA Splicing
Jul 08, 2019
Skyhawk Therapeutics Announces Addition of World Leading SAB Head & New VP of Oncology Biology
Feb 12, 2019
Pioneer in Taking RNA Therpeutics Through the Clinic Joins Skyhawk Therapeutics as Chief Medical Officer
Jan 04, 2019
Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets
Jun 26, 2018
Skyhawk Therapeutics Announces $40 Million Equity Investment Round
Jun 26, 2018
Skyhawk Therapeutics Announces Strategic Collaboration with Celgene to Discover and Develop Novel mRNA Splicing Modifiers using Skyhawk's STAR* Technology Platform